000056181 001__ 56181
000056181 005__ 20200221144211.0
000056181 0247_ $$2doi$$a10.1371/journal.pmed.1002008
000056181 0248_ $$2sideral$$a95333
000056181 037__ $$aART-2016-95333
000056181 041__ $$aeng
000056181 100__ $$aQuintero, E.
000056181 245__ $$aRisk of Advanced Neoplasia in First-Degree Relatives with Colorectal Cancer: A Large Multicenter Cross-Sectional Study
000056181 260__ $$c2016
000056181 5060_ $$aAccess copy available to the general public$$fUnrestricted
000056181 5203_ $$aBackground: First-degree relatives (FDR) of patients with colorectal cancer have a higher risk of developing colorectal cancer than the general population. For this reason, screening guidelines recommend colonoscopy every 5 or 10 y, starting at the age of 40, depending on whether colorectal cancer in the index-case is diagnosed at <60 or =60 y, respectively. However, studies on the risk of neoplastic lesions are inconclusive. The aim of this study was to determine the risk of advanced neoplasia (three or more non-advanced adenomas, advanced adenoma, or invasive cancer) in FDR of patients with colorectal cancer compared to average-risk individuals (i.e., asymptomatic adults 50 to 69 y of age with no family history of colorectal cancer). Methods and Findings: This cross-sectional analysis includes data from 8, 498 individuals undergoing their first lifetime screening colonoscopy between 2006 and 2012 at six Spanish tertiary hospitals. Of these individuals, 3, 015 were defined as asymptomatic FDR of patients with colorectal cancer (“familial-risk group”) and 3, 038 as asymptomatic with average-risk for colorectal cancer (“average-risk group”). The familial-risk group was stratified as one FDR, with one family member diagnosed with colorectal cancer at =60 y (n = 1, 884) or at <60 y (n = 831), and as two FDR, with two family members diagnosed with colorectal cancer at any age (n = 300). Multiple logistic regression analysis was used for between-group comparisons after adjusting for potential confounders (age, gender, and center). Compared with the average-risk group, advanced neoplasia was significantly more prevalent in individuals having two FDR with colorectal cancer (odds ratio OR] 1.90; 95% confidence interval CI] 1.36–2.66, p < 0.001), but not in those having one FDR with colorectal cancer diagnosed at =60 y (OR 1.03; 95% CI 0.83–1.27, p = 0.77) and <60 y (OR 1.19; 95% CI 0.90–1.58, p = 0.20). After the age of 50 y, men developed advanced neoplasia over two times more frequently than women and advanced neoplasia appeared at least ten y earlier. Fewer colonoscopies by 2-fold were required to detect one advanced neoplasia in men than in women. Major limitations of this study were first that although average-risk individuals were consecutively included in a randomized control trial, this was not the case for all individuals in the familial-risk cohort; and second, the difference in age between the average-risk and familial-risk cohorts. Conclusions: Individuals having two FDR with colorectal cancer showed an increased risk of advanced neoplasia compared to those with average-risk for colorectal cancer. Men had over 2-fold higher risk of advanced neoplasia than women, independent of family history. These data suggest that screening colonoscopy guidelines should be revised in the familial-risk population.
000056181 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI08-90717$$9info:eu-repo/grantAgreement/ES/ISCIII/PI10-00384$$9info:eu-repo/grantAgreement/ES/ISCIII/PI13-00719
000056181 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000056181 590__ $$a11.862$$b2016
000056181 591__ $$aMEDICINE, GENERAL & INTERNAL$$b7 / 154 = 0.045$$c2016$$dQ1$$eT1
000056181 592__ $$a6.418$$b2016
000056181 593__ $$aBiochemistry$$c2016$$dQ1
000056181 593__ $$aBiotechnology$$c2016$$dQ1
000056181 593__ $$aMolecular Biology$$c2016$$dQ1
000056181 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1
000056181 593__ $$aCell Biology$$c2016$$dQ1
000056181 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000056181 700__ $$aCarrillo, M.
000056181 700__ $$aLeoz, M.L
000056181 700__ $$aCubiella, J.
000056181 700__ $$aGargallo, C.
000056181 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, A.$$uUniversidad de Zaragoza
000056181 700__ $$aBujanda, L.
000056181 700__ $$aGimeno-García, A.Z.
000056181 700__ $$aHernández-Guerra, M.
000056181 700__ $$aNicolás-Pérez, D.
000056181 700__ $$aAlonso-Abreu, I.
000056181 700__ $$aMorillas, J.D.
000056181 700__ $$aBalaguer, F.
000056181 700__ $$aMuriel, A.
000056181 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000056181 773__ $$g13, 5 (2016), 1002008 [18 pp]$$pPLos Med.$$tPLOS MEDICINE$$x1549-1277
000056181 8564_ $$s909115$$uhttps://zaguan.unizar.es/record/56181/files/texto_completo.pdf$$yVersión publicada
000056181 8564_ $$s107621$$uhttps://zaguan.unizar.es/record/56181/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000056181 909CO $$ooai:zaguan.unizar.es:56181$$particulos$$pdriver
000056181 951__ $$a2020-02-21-13:11:57
000056181 980__ $$aARTICLE